Users consuming data from enterprise resources use Cognos as their main reporting tool for operational data. These videos are designed as both training tools, report training, and reference guides for individuals in the reporting environment. The videos listed below are based on user roles and licensing.
Using MotioCI within Cognos
Recover an Older Version of a Report
This video demonstrates how to revert to an older version of a Cognos report. MotioCI relieves you from needing to save multiple versions. Cognos users can now revert back to a previous version.
Restoring a Deleted Report
This video demonstrates how to restore a deleted Cognos report or folder. Cognos users can now recover deleted reports and folders.
Demonstration on creating a Cognos schedule, including creating a report view and setting prompt selections.
Cognos Analytics Authoring
Completion of COG 101 is required. Cognos Analytics Authoring offers report authoring capabilities including advanced formatting and filtering, prompt generation, and paging controls. This tool allows for a robust experience in data handling and report construction.
Videos (to be watched sequentially - total run time is under 2 hours)
Cognos is a web-based suite of tools from IBM that offers a full range of business intelligence (BI) capabilities including reports, analysis, dashboards, scorecards, mobile BI and more. Cognos is Purdue’s primary Business Intelligence(BI) tool and is used to access many of the university’s BI environments including those to access student-related data.
Cognos is the system Purdue uses for official reporting on Purdue student data. If you’d like to learn about how to request Cognos access, please visit the Business Intelligence Competency Center Website.
Helpful Resources
The following Cognos system reports (login required) are recommended by Accounting Services for Research and Sponsored Programs (ASRSP) for administrators to use when monitoring their unit's sponsored projects.
GM044 - Sponsored Project Portfolio
-
This report displays balances for active projects including totals for direct and indirect expenditures as well as encumbrances by department and/or principal investigator
-
It can run for negative balances only to monitor deficit spending
-
Drill through available by project to the GM045 - Sponsored Project Budget Statement
GM086 - Projects Balances Report
- Similar to Sponsored Project Portfolio, but with added data fields including ASRSP Grant and Contract Financial Administrator (GCFA) Name, Award ID/Sponsor ID, Start and End dates
- No drill through capability
- Recommended by ASRSP: run for current period, all Contract Statuses, Active Projects, and specify either a particular PI for Manager/Reviewer field or select particular department for a detailed view of the current financial status of your constituency. View in Excel 2007 Data file type.
GM045 - Sponsored Project Budget Statement
-
Displays direct and indirect expenditure totals by project against the total budget amount along with project demographic data
-
Dollars are broken out and shown by Current Accounting Period, Fiscal Year to Date, and Inception to Date
GM047 - Milestone (Deliverable) Report
- Used by department administrators and PIs in tracking upcoming deliverable due dates to assist in meeting sponsor and institutional requirements
GM091 - Sponsor Payments Received
- Presents details of payments received by contract, with a breakout by project
- Payment activity includes all forms of payments as well as a subset of write-offs and other maintenance items
- Note: For converted non-clinical awards, payment data prior to December 2008 is not available
GM092 - Subcontract Monitoring Report
- Displays a complete list of fully-executed subcontracts
- Current status for funding and disbursement
- Includes the burn rates (percent disbursed)
GM093 - Cost Share Commitment Status
- Presents revenue and expense data from NUFinancials Commitment Control for sponsored projects with cost sharing
- Grants users a multi-year view of budget, revenue and expense on cost share funds
- Provides a comprehensive view of all departments committing cost share funds to a given sponsored project
GM096 - Grants Transaction History Queries
- Displays expense and budget transactions on sponsored (grant) chart strings. This report, when downloaded to Excel, can be used in conjunction with ASRSP’s Expense Review Workbook template. The report contains two sections, “Expense Transaction Query” and “Budget Query”. When exported to Excel, the data will appear on separate tabs.
- This report is used by Principal Investigators, Department Administrators, and ASRSP to review detailed transaction history by contract or project id. It can reduce compliance risk by providing departments with easier access to and greater detail regarding expenses posted to grants.
GM097- Sponsored Project Actuals Balance Report
- GM097 Guide to Understanding
- GM097 ASRSP Formatting Recommendations
- The GM097 displays a comprehensive view of a research departments' entire research project portfolio, including non-clinical sponsored projects, cost-shared projects, and clinical trials.
- Non-clinical project balances are displayed Total Budget less Direct and F&A Expenditures and Encumbrances.
- Clinical project balances are displayed Cash Received less Direct and F&A Expenditures and Encumbrances, with Protocol numbers.
GL008 - Revenue and Expense Activity Report
SC016 - Open Encumbrances Report
GL069 - Financial Summary
Our annual list of 10 Breakthrough Technologies highlights the technological advances that we think will have the biggest impact on the world in the years to come.
The 35 Innovators Under 35 is our yearly opportunity to take a look at not just where technology is now, but where it’s going and who’s taking it there.
What is AI? It’s the quest to build machines that can reason, learn, and act intelligently, and it has barely begun. We cover the latest advances in machine learning, neural networks, and robots.
Face recognition | Machine learning | Robots | Voice assistants
The Big Story is a home for MIT Technology Review’s most important, ambitious reporting—stories that take a deep look at the technologies that are coming next and what they will mean for us and the world we live in.
Biotechnology is the industry that uses the molecules of life (DNA, RNA, and proteins mostly) to treat and diagnose disease. We report on the latest biomedical science and technological research.
CRISPR | DNA testing | Genetic engineering | Genomic medicine
What is a blockchain? Distributed ledger technology underlies cryptocurrencies like bitcoin and could be the future of money, security, and online privacy. But there’s also a ton of hype.
Bitcoin | Cryptocurrency | Ethereum | ICOs | Smart contracts
Climate change is making the Earth a warmer and weirder place, forcing researchers, companies and governments to understand, confront and adapt to rising dangers.
Battery technology | Carbon sequestration | Clean energy | Electric cars | Geoengineering
Computer technology news and in-depth analysis of computer tech, looking at the latest advances in computing being driven by innovations in everything from microchips to quantum computing.Cloud computing
Cybersecurity | Edge computing | Microchips | Quantum computing | Supercomputing
You can read our most essential coverage of the coronavirus/COVID-19 outbreak for free, and also sign up for our coronavirus newsletter. But please consider subscribing to support our nonprofit journalism.
A look at how technologies from AR/VR, brain-computer interfaces, and chip implants to health trackers, biometrics and social media are changing the most basic aspects of human life—work, friendship, love, aging, sickness, parenting, learning, and building community.
AR | Biohacking | Brain-computer interface | VR
Covid-19 has altered our lives in countless ways. We’re tracking technology that’s responding to the pandemic, with support from The Rockefeller Foundation.
Google, Facebook, Apple, Amazon, and other Silicon Valley Big Tech companies are built on innovation. But how are these corporate behemoths dealing with the ramifications of their power?
Amazon | Apple | Facebook | Google |
Governments around the world are trying to Improve urban life by adopting digital technologies and creating Smart Cities filled with sensors. Who are these projects benefiting and how smart are they?
5G | IoT | Self-driving cars
Humanity is pushing further outside of our atmosphere. We take a look at the space tech coming out of places like NASA, SpaceX, and Blue Origin that is powering the space exploration of tomorrow.
Astronomy | NASA news | Space exploration | SpaceX news | The Moon
Who’s responsible when technology causes harm? We look at how the world is dealing with problems like fake news and misinformation, AI bias, Big Tech’s power, genetic discrimination, privacy intrusions, mass surveillance, and more.
In today’s world of “business professional” and “business casual” attire, it can be tricky to know the appropriate way to dress for an interview, for work at a conservative company such as a financial institution, or for a place where things are a little more laid back. What makes it even trickier is that what is considered “business professional” at one company, such as non-profit or a software organization, might be considered “business casual” at an accounting firm.
So what is a person to do?!
The examples on Pinterest boards reflect this difference in standards between organizations, and you'll see a great deal of overlap.
Here are a few tips:
- For interviews, it is always better to be overdressed than underdressed. Even if employees at an organization dress fairly casually, YOU are the one looking for a job and the one being compared against other candidates, so you should always wear professional attire.
- When you are offered a position, prior to your first day it is completely appropriate to ask your soon-to-be supervisor about the written or unwritten company dress code.
- If the verbal or written dress code is vague, it is better to err on the side of caution and overdress for your first week, paying attention to those around you to learn company norms and expectations. Keep in mind that dress code is something that many supervisors find stressful to enforce. So, if you notice a wide range of attire at the work site, it is best to go with the more conservative look.
Casual Days
- If you are at an organization that has limited "business casual" days, the key to remember is that "business casual" is typically one step below "business professional".
- So if "business professional" means a suit for both men and women at one organization, then "business casual" may be dress pants or skirts without the jacket or tie (for men). If "business professional" means nice pants/skirts (but not suits) at another location, then "business casual" could be khakis and a polo or a casual skirt.
- The key? Be aware, ASK, and err on the side of caution.
Regardless of business professional or business casual, women should always avoid showing cleavage and mid-drifts, as well as avoid clothing that is too tight or too short. Both men and women should always choose clothing that covers tattoos, and jewelry should be kept to a minimum (no earrings on men!).
Establishing Connection...
A place to explore new creative opportunities and advance your skills, the School of Continuing and Professional Studies offers a taste of the Pratt experience in an approachable and flexible format. From workshops to semester-long courses, in person or virtually, you’ll learn from leading Pratt faculty, create connections across disciplines, and earn digital credentials for select programs—all fueled by the latest technology and studio environments.
Chemical professionals should seek to advance chemical science while striving for the highest standards of scientific integrity. This includes sharing ideas and information, keeping accurate and complete records, and giving due credit to the contributions of others. Undisclosed conflicts of interest and scientific misconduct, including fabrication, falsification, and plagiarism, are incompatible with this code.
Chemical professionals should be aware of laws and regulations related to the professional conduct of science to ensure that their profession is practiced safely and appropriately.
Chemical professionals should be actively concerned with the health and safety of co‐workers, consumers, and the community. Professionals have a responsibility to serve the public interest and to further advance scientific knowledge. This includes ensuring that public comments are made with care and accuracy to avoid unsubstantiated, exaggerated, or premature statements.
Chemical professionals should treat others with respect and will not engage in discrimination, harassment, bullying, dishonesty, fraud, misrepresentation, coercive manipulation, censorship, or other misconduct. Such actions apply to all professional, research, and learning environments, regardless of whether or not the action alters the content, veracity, or meaning of research findings, and regardless of whether or not the action affects the planning, conduct, reporting, or application of science.
Chemical professionals should take responsibility to act or intercede where possible to prevent misconduct. This includes reporting suspected research misconduct, as well as any discrimination, harassment, bullying, dishonesty, fraud, misrepresentation, coercive manipulation, or censorship.
Chemical professionals should be mindful of Implicit Bias and Unconscious Bias and strive to avoid all bias based on race, gender, age, religion, ethnicity, nationality, sexual orientation, gender expression, gender identity, presence of disabilities, educational background, or other personal attributes.
Chemical professionals should strive to do their work in ways that are safe and sustainable for the environment. This includes continuing to work to develop sustainable products and processes that protect the health, safety, and prosperity of future generations.
Chemical professionals should serve clients faithfully and incorruptibly, respect confidentiality, advise honestly, and charge fairly. Additionally, they should promote and protect the legitimate interests of their employers, comply with safety policies and procedures, fulfill obligations, and safeguard proprietary and confidential business information.
Chemical professionals should strive for continual professional growth both personally and more broadly in the tutelage of others as a trust conferred by society. Professionals have a responsibility to understand limitations of their knowledge, remain current with developments in their field, learn with and encourage others.
For more information about the Department of Career and Professional Advancement, please see our Contacts List.
Topic selection is the process for deciding which courses NICE will produce technology appraisal guidance on. NICE aims to consider all new significant drugs and indications. Health technologies referred to the NICE technology appraisals programme include:
- medicinal products
- medical devices
- diagnostic techniques
- surgical procedures or other therapeutic techniques
- therapeutic technologies other than medicinal products
- systems of care
- screening tools
The subject selection process has been designed to support the technology appraisal process so that courses chosen will add value and support healthcare professionals and others to provide care of the best possible quality, which offers the best value for money.
NICE manages this process on behalf of the Department of Health and Social Care. NICE can only begin to appraise a technology when it has been formally referred by the Secretary of State for Health and Social Care.
The aims of the subject selection process are to:
- ensure NICE addresses courses of importance to patients, carers, healthcare professionals, commissioners, providers and public health
- help make the best use of NHS resources
- coordinate the selection of courses using a standard selection process
- make subject selection as rapid as possible to minimise the period of uncertainty before guidance is issued
- ensure that all subject selection activities are inclusive, open, transparent and consistently applied
- ensure that all stages of the process are well documented with clear operating procedures and responsibilities and that throughout there is clear and visible progress tracking for all courses considered
- ensure there are appropriate governance structures and arrangements in place with all relevant parties.
Most courses are identified by the National Institute for Health Research Innovation Observatory at the University of Newcastle. This centre notifies NICE about key, new and emerging healthcare technologies that might be suitable for NICE technology appraisal. It aims to notify NICE of new drugs in development 20 months before marketing authorisation and new indications 15 months before marketing authorisation. These time frames are required by NICE to enable guidance to be published as close as possible to product launch.
Suggestions for technology appraisal guidance on a new medicinal product (that has not yet received a marketing authorisation) should be made by the relevant company through UKPharmaScan. Healthcare professionals, researchers and patients can also suggest potential technologies for NICE to appraise by contacting the National Institute for Health Research Innovation Observatory.
Elimination and filtering
Topic selection decisions are based on the consideration of each potential subject against elimination and prioritisation criteria. The elimination criteria filter out courses unsuitable for guidance development through the technology appraisal programme. A subject will not be considered if the technology has not been granted a marketing authorisation (or equivalent) or if there are no plans for it to receive a marketing authorisation (or equivalent) or if it is identical to:
- NICE guidance that has been published
- NICE guidance that is in development
- a subject currently in the subject selection process
- a subject that has been considered and eliminated from the subject selection process
- a subject that has been considered in the last 3 years and not been prioritised
- a subject widely accepted and implemented on the basis of existing published guidance from the Department of Health and Social Care, Arm’s Length Body or other government departments (excluding national service frameworks, white papers and planning priorities guidance)
The following subject areas are also outside the remit of technology appraisal guidance development at NICE:
- Population screening - falls under the remit of the UK National Screening Committee.
- Vaccination - generally falls under the remit of the Joint Committee on Vaccination and Immunisation. However, NICE does consider therapeutic vaccines.
- HIV technology or therapy - falls under the remit of the British HIV Association. However, there may be situations when the Department of Health and Social Care considers that a NICE appraisal of an HIV technology or therapy would be helpful to the NHS and these will be dealt with on a case-by-case basis.
- Haemophilia - for technologies which are considered suitable for existing national procurement processes.
Topics are not considered unless:
- there is likely to be significant benefit to patients in terms of administration, efficacy or improved side-effect profile and
- the new formulation or technology is likely to be at a significantly different price to current standard treatment and
- there is appropriate evidence, either available or anticipated to be available in the near future, to support the appraisal (refer to section 3.3 of the Guide to the methods of technology appraisal) and
- the relevant clinical question(s) can be addressed by applying the technology appraisal methodology. This may mean excluding courses on which technology appraisal guidance would not add value without broader guidelines on the clinical pathway.
Elimination and filtering is done by the Consultant Clinical Adviser in the subject selection team and includes seeking expert opinion and engaging with the relevant National Clinical Directors. The filtering recommendations are considered by an internal group at NICE, and shared with the Department of Health and Social Care and NHS England.
Prioritisation
The importance of each subject is considered against prioritisation criteria prioritisation criteria (PDF) that help the Secretary of State for Health and Social Care decide which courses should be referred to NICE for guidance development through the technology appraisal programme. This includes consideration of the population size, disease severity, resource impact and the value that NICE could add in carrying out a technology appraisal. The prioritisation criteria are:
- Is the technology likely to result in a significant health benefit, taken across the NHS as a whole, if given to all patients for whom it is indicated?
- Is the technology likely to result in a significant impact on other health-related Government policies?
- Is the technology likely to have a significant impact on NHS resources if given to all patients for whom it is indicated?
- Is there significant inappropriate variation in the use of the technology across the country?
- Is NICE likely to be able to add value by issuing national guidance? For example, without such guidance is there likely to be significant controversy over the interpretation or significance of the available evidence on clinical and cost effectiveness?
Prioritisation is also done by the Consultant Clinical Adviser in the subject selection team and is informed by the external expert opinion already sought during filtering. The National Institute for Health Research Innovation Observatory at the University of Newcastle develops technology briefings for potential appraisal topics.
Relevant companies have the opportunity to comment on these technology briefings before the prioritisation recommendations are considered by an internal group at NICE, and shared with the Department of Health and NHS England. The group at NICE meets to decide the next steps for each subject being considered, to ensure the timely production of guidance. The group considers each subject and decides whether it is potentially suitable for NICE appraisal and as a result, whether the scope should be sent out for consultation.
Summary information on subject progress is published on the NICE website. The list of potential courses is handed over to the technology appraisal scoping team to develop the draft scopes for consultation.
Medicinal products marketed in England that do not meet the criteria for referral into the technology appraisal programme can be considered for the highly specialised technologies programme or for a new medicines evidence summary to help inform local decision-making.
Biosimilars
NICE’s approach on biosimilars is:
a. NICE will consider similar biological medicinal products notified to it by the National Institute for Health Research Innovation Observatory for referral to the Technology Appraisal subject selection process.
b. These products will usually be considered in the context of a Multiple Technology Appraisal in parallel with their reference products in the indication under consideration.
c. In other circumstances, where it is considered a review of the evidence for similar biological medicinal product is necessary, NICE will consider producing an ‘Evidence summary new medicine’.
d. NICE technology appraisals will use the name of the active drug substance, including reference products and brand named similar biological medicinal products in its documentation where appropriate to inform clinical decision making and to reflect the remit received from Ministers.
e. The Department of Health in England has confirmed that a technology appraisal remit referred to NICE enables NICE to decide to apply the same remit, and the resulting guidance, to relevant licensed biosimilar products which subsequently appear on the market.
f. Evidence summaries will use the brand names of the medicines because substitutability and interchangeability cannot be assumed. Evidence summaries do not make recommendations hence the decision regarding the choice of biosimilar or originator biologic for an individual patient rests with the responsible clinician in consultation with the patient.
Companies wanting to suggest new pharmaceutical products
Companies that want to suggest that NICE develops guidance on a new pharmaceutical product (one that is not yet licensed or used within the NHS) should notify UK PharmaScan. More information is on the Pharmascan website. Alternatively, please contact the National Institute for Health Research Innovation Observatory.
